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Chronic obstructive pulmonary disease (COPD) constitutes a major cause of morbidity and mortality. 
Genome wide association studies have shown significant associations between airflow obstruction or 
COPD with a non-synonymous SNP in the TNS1 gene, which encodes tensin1. However, the expression, 
cellular distribution and function of tensin1 in human airway tissue and cells are unknown. We therefore 
examined these characteristics in tissue and cells from controls and people with COPD or asthma. 
Airway tissue was immunostained for tensin1. Tensin1 expression in cultured human airway smooth 
muscle cells (HASMCs) was evaluated using qRT-PCR, western blotting and immunofluorescent 
staining. siRNAs were used to downregulate tensin1 expression. Tensin1 expression was increased 
in the airway smooth muscle and lamina propria in COPD tissue, but not asthma, when compared 
to controls. Tensin1 was expressed in HASMCs and upregulated by TGFβ1. TGFβ1 and fibronectin 
increased the localisation of tensin1 to fibrillar adhesions. Tensin1 and α-smooth muscle actin (αSMA) 
were strongly co-localised, and tensin1 depletion in HASMCs attenuated both αSMA expression and 
contraction of collagen gels. In summary, tensin1 expression is increased in COPD airways, and may 
promote airway obstruction by enhancing the expression of contractile proteins and their localisation to 
stress fibres in HASMCs.
Chronic obstructive pulmonary disease (COPD) constitutes a major cause of morbidity and mortality with more 
than 200 million people affected worldwide1,2. It is characterised by irreversible airway narrowing which limits 
airflow, resulting in breathlessness and in severe cases, respiratory failure3. The most common cause is tobacco 
smoking4. COPD is characterised by airway remodeling that involves thickening of the airway wall and the airway 
smooth muscle (ASM) layer, hypersecretion of mucous and metaplasia of epithelial cells5,6. Airway wall thickness 
results from an increase in each of the airway wall compartments, including the epithelium, ASM and lamina 
propria7. Under normal conditions ASM has a critical role in regulating the tone of the airways and distribution of 
airflow by maintaining a balance between contractile and dilatory processes8. In COPD, changes occur in airway 
smooth muscle, notably in the small airways7,9, and ASM cells mediate deposition of collagens, fibronectin and 
laminin in extracellular matrix10,11.
Recent evidence suggests that gene-environment interactions constitute a major factor for the development 
of COPD12. Genome wide association studies (GWAS) have shown a significant association between a non syn-
onymous single nucleotide polymorphism (SNP) in the coding region of the tensin1 gene (TNS1) and COPD13, 
as well as airflow obstruction14 and early childhood wheeze15. Tensin1 is a 220 kDa cytoplasmic phosphoprotein, 
which localises to integrin-mediated focal and fibrillar adhesions16. These adhesions provide a bi-directional link 
between the extracellular matrix and the cytoskeleton17. A phosphotyrosine domain in the C-terminal region 
of tensin1 facilitates an interaction with the α5β1 integrin, which itself binds to the extracellular matrix protein 
fibronectin. Furthermore, an actin-binding domain is located on the N-terminal of tensin1 enabling interaction 
with the actin filaments, and in particular the F-actin protein18,19. The interactions of tensin1 with these intra-
cellular and extracellular molecules contribute to its involvement in cell signaling and function. However, the 
pattern of expression and (patho)physiological role of tensin1 in human airways is not known.
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We have therefore characterised the localisation of tensin1 and its cellular function in the context of COPD. 
We have further investigated whether the TNS1 SNP (2q35, rs257114 C > T, resulting in R1197W amino acid 
substitution) could play a pathogenic role in COPD.
Results
Clinical characteristics. The clinical characteristics of the controls, COPD and asthma subjects used for 
immunohistochemistry and cell culture studies are summarised in Tables 1–3.
Tensin1 immunoreactivity is increased in both the airway smooth muscle and lamina propria 
in patients with COPD but not asthma. To identify the expression and cellular localisation of tensin1 in 
human airways in vivo, tissue was immunostained for tensin1. Immunostaining was performed on non-COPD 
control (n = 11) and COPD (n = 13) airway tissue from lung resections, and healthy (n = 9) and asthmatic 
(n = 10) bronchial biopsies. Positive tensin1 staining was observed in the apical epithelium, ASM bundles and 
lamina propria (Fig. 1A,B). Quantification of tensin1 immunostaining was performed using a thresholding 
technique as previously described20. A significant increase in tensin1 immunostaining was detected in both the 
lamina propria and ASM in COPD compared to non-COPD control tissue (Fig. 1C). There was no significant 
difference between COPD and control airway epithelium (Fig. 1C).
Since smoking is the most common causative factor for COPD and the COPD group had a greater smoking 
history than non-COPD controls, we examined the correlation of tensin1 and tobacco smoking. The extent of 
tensin1 immunostaining was not affected by the smoking status of non-COPD control individuals (Fig. 1C), and 
there was no correlation between tensin1 immunostaining and smoking in the COPD subjects in any compart-
ment (p > 0.05 for all comparisons). The COPD patients were also a little older than the control group (Table 1) 
but tensin1 immunostaining was not correlated with age in any tissue compartment in either non-COPD controls 
or COPD subjects (p > 0.05 for all comparisons).
Tensin1 immunostaining was not increased in any airway compartment in asthma (Fig. 1C). Tensin1 immu-
nostaining correlated positively with the area of the smooth muscle bundles in COPD subjects (R = 0.6286, 
p = 0.0286) (Fig. 1D). Isotype control staining was negative. Specificity of the antibody for tensin1 was confirmed 
by immunoprecipitation (Figure S1A in the Supplementary Information).
Human airway smooth muscle cells express tensin1 mRNA, which is up-regulated by TGFβ1. 
As tensin1 was most strongly increased in the ASM in COPD subjects when compared to controls, its role in cul-
tured HASMCs was studied further. We studied expression at the mRNA and protein level in HASMCs derived 
from healthy, asthmatic and COPD airway tissue collected at bronchoscopy, basally and following stimulation 
with TGFβ1 or fibronectin.
Tensin1 mRNA was expressed at high levels in HASMCs, with no differences detected between patients with 
COPD or asthma and healthy controls (Fig. 2A). Tensin1 mRNA expression by HASMCs was significantly upreg-
ulated by TGFβ1 stimulation and to a similar extent in both healthy (n = 3) and COPD (n = 3) subjects (Fig. 2B). 
Overall, in vitro, tensin1 protein expression was similar between HASMCs derived from healthy and COPD tissue 
(Fig. 2C) under basal conditions. As tensin1 facilitates integrin binding to fibronectin, we examined whether 
culturing HASMCs on fibronectin altered tensin1 distribution, but there was no significant change (Fig. 2D). 
However, stimulating HASMCs cultured on plastic or fibronectin with TGFβ1 significantly increased the length 
of fibrillar adhesions defined by tensin1 immunostaining in HASMCs derived from both healthy and COPD 
donors (Fig. 2D). In contrast to the transcriptomic data, and findings in tissue ex vivo, these stimuli did not signif-
icantly increase overall tensin1 protein levels in the HASMCs, assessed by immunostaining and greyscale analysis 
(Supplementary Fig. S1B).
siRNA transfection achieved around 92% silencing of tensin1 mRNA after 48 hours, as quantified by the 2−
(ΔCt) method (n- = 3) (Supplementary Fig. S1C). Silencing of tensin1 did not have any effect on the survival or 
proliferation of HASMCs in culture (n = 4 healthy and n = 4 COPD) assessed by the MTS assay (Supplementary 
Fig. S2A). Tensin1 silencing was associated with a small but significant reduction in TGFβ1 secretion in 
COPD-derived HASMCs, but this was not evident in supernatants when HASMCs derived from healthy subjects 
were used (Fig. 2E).
Taken together, these data indicate that the apparent increase in cellular tensin1 protein signal in COPD ASM 
in vivo may be driven by interactions with the abnormal matrix in disease rather than inherent changes within the 
cells in the disease state. TGFβ1 and fibronectin stimulation does not appear to account for this, but they do alter 
the cellular distribution of the protein to associate more with fibrillar adhesions of greater length in HASMCs 
from both healthy and COPD tissue.
Tensin1 stimulates αSMA expression and interacts with it in HASMCs, and mediates contraction. 
We next assessed whether the increased length of fibrillar adhesions following TGFβ1 stimulation related to 
increased interactions with, and/or increased expression of, αSMA in HASMCs derived from healthy controls 
(n = 3) and COPD individuals (n = 3). Colocalisation and close physical association of tensin1 and αSMA was 
demonstrated by co-immunoprecipitation (co-IP, Fig. 3A) and confocal microscopy (Fig. 3B). In all conditions, 
strong co-localisation of tensin1 and αSMA immunofluorescence was observed (Fig. 3B). Quantification of the 
degree of colocalisation by overlap analysis (Mander’s overlap coefficient = 0.8 and Pearson’s correlation~0.6) 
revealed strong spatial colocalisation between the two proteins (Fig. 3C).
Tensin1 silencing significantly reduced αSMA expression at the mRNA (Fig. 4A) and protein levels 
(Figs. 4B,C, S2B) in both non-stimulated and TGFβ1-stimulated HASMCs derived from healthy and COPD lung 
tissue. There were no apparent differences relating to the health/disease status of the original lung tissue.
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To assess the mechanistic significance of tensin1- αSMA interactions, collagen gel contraction assays21,22 were 
performed to study HASMC contraction. A representative example of these experiments can be seen in Fig. S3 
(Supplementary Information). These studies indicated that tensin1 depletion greatly reduced HASMC contraction, 
with no difference between HASMCs derived from healthy (n = 4) and COPD (n = 4) subjects (Fig. 5A). Collagen 
gel contraction increased significantly following stimulation with the contractile agonist bradykinin in controls 
(untreated cells, transfection reagent alone, siCON control), but not in cells subjected to tensin1 knockdown 
(Figs. 5B and S4 [Supplementary Figure]). Taken together these data indicate that tensin1 interactions with αSMA 
Lung resections
Statistical 
analysis
non-COPD Lung 
resections (n = 11)
COPD Lung 
resections (n = 13)
Age (years) 66.9 ± 8.6 74.3 ± 9.4 p = 0.0284
Gender (M/F) 8/3 9/4 NS
FEV1(% predicted) 83.3 ± 9.5 68.2 ± 10.9 p = 0.0004
FEV1/FVC ratio (%) 79.8 ± 6.7 60.0 ± 8.8 p < 0.0001
Smoking (pack years) 15.5 ± 15.3 34.7 ± 16.6 p = 0.0024
Inhaled corticosteroid dose (µg) 0 0 NS
Severity NA GOLD 1 (2) & GOLD 2 (11) NA
Table 1. Clinical characteristics of non-COPD controls and COPD subjects used for immunohistochemistry. 
Data are mean ± SD unless otherwise stated (SD: Standard deviation, FEV1: forced expiratory volume at second 
1, FVC: forced vital capacity, CI: confidence interval, NA: not applicable; NS: non-significant).
Bronchial biopsies
Statistical 
analysis
Healthy Biopsies 
(n = 9)
Asthmatic Biopsies 
(n = 10)
Age (years) 31.6 ± 15.9 37.7 ± 12.4 NS
Gender (M/F) 5/4 4/6 NS
FEV1(% predicted) 102.2 ± 11.6 79.4 ± 13.2 p = 0.0117
FEV1/FVC ratio (%) 81.4 ± 7.4 66.9 ± 8.4 p = 0.0180
Smoking (pack years) 0.4 ± 1.2 0.9 ± 2.3 NS
PC20 methacholine (mg/ml), geometric mean (95% CI) >16 6.8 (2.9–10.5) p = 0.0006
Reversibility to β-agonist (%) 1.6 ± 4.9 19.7 ± 25.1 p = 0.0465
Serum IgE (KU/L), geometric mean (95% CI) 43.8 (16.2–71.4) 172.1 (97.5–246.6) p = 0.0054
Inhaled corticosteroid dose (µg) 0 192.9 ± 148.4 p = 0.0008
Severity NA Mild (3), Moderate (2) & Severe (5) NA
Age of onset NA 20.3 ± 14.3 NA
Table 2. Clinical characteristics of healthy controls and asthma subjects used for immunohistochemistry. Data 
are mean ± SD unless otherwise stated (SD: Standard deviation, FEV1: forced expiratory volume at second 1, 
FVC: forced vital capacity, CI: confidence interval, NA: not applicable; NS: non-significant).
Human airway smooth muscle cells Statistical 
analysisHealthy COPD Asthma
Age (years) 42.5 ± 4.7 69.7 ± 1.5 44.5 ± 5.2 p = 0.0001
Gender (M/F) 5/7 7/3 6/3 NS
FEV1(% predicted) 95.6 ± 3.2 54.4 ± 5.4 96.5 ± 4.8 p < 0.0001
FEV1/FVC ratio (%) 80.2 ± 1.5 53.7 ± 3.1 79.1 ± 2.4 p < 0.0001
Pack Years (y) 1.7 ± 0.9 41.7 ± 4.5 6.1 ± 5.4 p < 0.0001
PC20 methacholine (mg/ml), geometric mean (95% CI) 9.3 (3.9–14.6) ND 4.3 (1.3–7.3) p = 0.0463
Reversibility to β-agonist (%) NA ND −1.3 ± 2.4 NA
Serum IgE (KU/L), geometric mean (95% CI) 4.9 (4.2–5.5) ND 498 (396.3–599.6) p < 0.0001
Inhaled corticosteroid dose (µg) 0 500 633.3 ± 190.5 p = 0.0012
Severity NA GOLD 1 – GOLD 4 GINA 1 – GINA 5 NA
Age of Onset NA 57 ± 2.3 31.5 ± 3.6 p = 0.0005
Table 3. Clinical characteristics of healthy controls, COPD and asthmatic subjects used for cell culture studies. 
Data are mean ± SD unless otherwise stated (SD: Standard Deviation, FEV1: forced expiratory volume at second 
1, FVC: forced vital capacity, CI: confidence interval, NA: not applicable, ND: not done & NS: non-significant).
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Figure 1. Tensin1 immunostaining in non-disease controls and COPD lung resection and healthy and 
asthmatic bronchial biopsies. (A) Examples of tensin1 and isotype control immunostaining in COPD (n = 13) 
and non-COPD lung resections (n = 11) (EP: epithelium; ASM: airway smooth muscle; LP: lamina propria). 
(B) Examples of tensin1 and isotype control immunostaining in bronchial biopsies from patients with asthma 
(n = 10) and healthy controls (n = 9) (EP: epithelium; ASM: airway smooth muscle; LP: lamina propria, RBM: 
reticular basement membrane). (C) The extent of tensin1 immunostaining in airway epithelium, airway smooth 
muscle and lamina propria analysed using threshold measurements. Increased tensin1 immunostaining was 
observed in the airway smooth muscle (**p = 0.007) and lamina propria (*p = 0.012) in COPD subjects when 
compared to non-COPD controls (Mann-Whitney unpaired non parametric test). Tensin1 immunostaining 
in lung resections was not affected by the smoking status of non-COPD control individuals. (D) Tensin1 
immunostaining in COPD subjects was positively correlated with the smooth muscle bundle area, calculated by 
Pearson’s correlation (R = 0.6286, p = 0.0286).
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Figure 2. Tensin1 mRNA and protein expression in HASMCs in health and disease and the effect of TGFβ1 
and fibronectin. (A) Quantitative Reverse Transcription -PCR (qRT-PCR) was used to quantify tensin1 mRNA 
expression in HASMCs isolated from healthy donors and patients with COPD or asthma using the 2^-(ΔCt) 
method (n = 7 of each, Mean ± SEM). (B) Tensin1 mRNA expression in human airway smooth muscle cells 
(HASMCs) was increased following TGFβ1-dependent stimulation in both COPD (n = 3) (*p = 0.0418) and 
healthy (n = 3) (**p = 0.0042) donors (Tukey’s multiple comparison test as part of one-way ANOVA, one-way 
ANOVA test: **p = 0.0019). (C) HASMC tensin1 immunofluorescent staining was measured by grey scale 
intensity in n = 6 healthy and n = 6 COPD subjects. No difference was observed in the grey scale intensity of 
tensin1 immunostaining in the two phenotypes (Mean ± SEM). (D) Cells were stimulated with TGFβ1 and/
or fibronectin. Stimulation with TGFβ1 and fibronectin did not significantly increase the grey scale intensity 
of tensin1. However, the length of fibrillar adhesions was significantly increased in HASMCs stimulated with 
TGFβ1 alone (*p = 0.0386) and TGFβ1 + fibronectin (***p = 0.0002) (Dunnett’s multiple comparison test as 
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increase αSMA expression, are increased in association with increased fibrillar adhesion length in HASMCs fol-
lowing TGFβ1 stimulation, and that these responses enhance contraction, irrespective of disease status.
Expression of the R1197 and R1197W tensin1 variants in healthy, asthmatic and COPD HASMCs. 
Having characterised tensin1 expression in COPD airway tissue and TGFβ1-stimulated HASMCs, and confirmed 
its interaction with αSMA was a key mediator of HASMC contraction, we then assessed the pathogenic potential 
of the R1197W mutation. RFLP analysis was used to genotype subjects for the presence of the polymorphism as its 
presence results in disruption of the formation of a restriction enzyme site (Fig. 6A). pEGFP constructs contain-
ing the full length of TNS1 cDNA with the C or T alleles were used as controls to validate the method (Fig. 6B). In 
Fig. 6C, the PCR-RFLP detection assay can be seen demonstrating the presence of the C or T alleles in HASMCs 
from healthy or COPD subjects. RFLP analysis revealed the predominant presence of the C/C homozygous geno-
type (which generates R1197) in healthy controls (11 of the 14 tested), and the heterozygote C/T or homozygous 
T/T (R1197W) genotype in COPD donors (12 of the 12 tested) (p < 0.0001) (Table 4). This indicates a strong link 
between the R1197W amino acid change and COPD, consistent with the GWAS signal (p = 1.11 × 10–12) [14]. 
In patients with asthma ranging from mild to severe, 8 of 9 samples tested were the heterozygote C/T or homozy-
gous T/T genotype, similar to COPD (Table 4). Taken together, these data suggest the mutation is a risk factor for 
obstructive airway disease as a whole, but the lack of increased tensin1 protein expression in asthmatic airways 
suggests different handling of tensin1 in these two conditions despite a frequently shared genotype.
qRT-PCR demonstrated similar tensin1 mRNA expression levels between the different TNS1 genotypes in 
HASMCs (Fig. 6D).
HASMCs were transfected with pEGFP constructs containing full length TNS1 cDNA with either the C or T 
allele and both constructs revealed similar transfection efficiency. Overexpression of tensin1 using pEGFP con-
structs containing the full length of TNS1 cDNA with the C or T alleles also did not have any effect on survival or 
proliferation (Supplementary Fig. S5B). Since the TNS1 SNP does not appear to affect transcription or translation 
of the TNS1 gene product tensin1, we further hypothesised that the mutation’s effects were likely to be mediated 
by differential turnover. Tensins are known to be highly susceptible to proteolysis23. Consistent with this, the 
mutation changes the predicted proteolytic sensitivities of tensin1 as assessed by ‘PeptideCutter’ prediction tool 
(Fig. 6E). Moreover, western blot analysis of HASMC lysates derived from healthy and COPD patient tissue 
provides some support for this hypothesis with a differential cleavage profile observed between the two (Fig. 6E). 
Much of the tensin1 protein from COPD-derived HASMCs appeared to be proteolytically modified, whilst that 
from HASMCs derived from healthy tissue appeared to be present solely in its full-length, 220 kDa form (Fig. 6E).
Discussion
Modern genetic approaches such as GWAS can provide powerful insight in understanding disease by identifying 
novel pathogenic mutations and highlighting important pathways that may mediate the pathological response. 
This study follows on from the GWAS findings that a non synonymous SNP in the coding region of TNS1 is 
associated with COPD risk. We therefore assessed the roles and interactions of tensin1 in healthy, asthmatic and 
COPD airways. We have demonstrated for the first time that tensin1 is expressed in the apical airway epithelium, 
ASM bundles and airway lamina propria in both non-COPD control and COPD lung resections, and healthy and 
asthmatic endobronchial biopsies. A significant increase in tensin1 immunostaining was detected in the ASM 
and lamina propria in COPD subjects when compared to non-COPD controls, but no differences were evident 
between asthma and health. Tensin1 mRNA and protein expression were present in cultured HASMCs. Of note, 
tensin1 co-localised and interacted physically with αSMA in actin stress fibres, and influenced αSMA expression, 
as tensin1 silencing led to downregulation of αSMA protein. As a result, tensin1 appears to make a critical contri-
bution to the contractile properties of HASMCs.
Tensin1 protein expression was upregulated in the ASM bundles in COPD compared to non-COPD controls, 
but not in cultured HASMCs, suggesting that the in vivo findings are regulated by local factors that are lost in 
cell culture. TGFβ1 is a candidate molecule regulating this in vivo as it is upregulated in COPD airways24, and we 
found that tensin1 mRNA expression was markedly upregulated by TGFβ1 in HASMCs in vitro. This is in keep-
ing with the effects of TGFβ1 on tensin1 expression in parenchymal lung fibroblasts obtained from patients with 
idiopathic pulmonary fibrosis25. However, TGFβ1 did not have a detectable effect on total tensin1 expression in 
HASMCs, but instead altered its intracellular distribution promoting the formation of long tensin1-containing 
fibrillar adhesions. To account for the increased overall levels of tensin1 protein evident in COPD airways relative 
to asthma and healthy tissue biopsies, factors in addition to TGFβ1 are likely to contribute. These factors would 
be less critical in asthmatic than COPD patients. Candidate factors would include other pro-inflammatory medi-
ators present in COPD, the airway response to cigarette smoke and associated epigenetic changes, or the response 
to impaired airway stretch present in COPD. These various hypotheses will need testing in future work, but may 
explain why tensin1 expression was not increased in asthmatic airways.
Tensins are known to play a key role in remodeling the extracellular matrix through their interactions with 
integrins18,25, and so the high expression in patients with COPD may be particularly relevant to the fixed airflow 
part of one-way ANOVA, one-way ANOVA test: ***p = 0.0004). Data shown is pooled COPD and healthy 
donors which did not differ (n = 3 of each, Mean ± SEM). (E) Cells were transfected with siRNA directed 
against tensin1 and supernatants were assessed for TGFβ1 expression using ELISA in both COPD (n = 4) and 
healthy donors (n = 4) (Mean ± SEM). Tensin1 depleted HASMC supernatants derived from COPD subjects 
had a small but significant reduction of TGFβ1 secretion when compared to controls (*p = 0.0477) (paired 
t-test).
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obstruction and small airway fibrosis present in COPD. This would be in keeping with the pro-fibrotic role of ten-
sin1 identified in patients with idiopathic pulmonary fibrosis25. In addition, an actin-binding domain is located 
on the N-terminal of tensin1 enabling interaction with actin filaments of the cytoskeleton, specifically within 
fibrillar adhesions that cause cellular stiffening in IPF25. The co-localisation of tensin1 with αSMA within stress 
fibres, and the marked downregulation of αSMA following tensin1 silencing, suggest feedback between tensin1 
gene transcription and/or protein expression and factors regulating αSMA gene regulation. The fact that there 
were differences in the demographics of the groups providing HASMCs for culture, but no difference in the way 
their HASMCs behave in culture, indicates that the role of tensin1 in ASM contraction is a fundamental role 
irrespective of disease status and patient characteristics. Our data do not permit relative quantitative compar-
isons of the direct contribution tensin1 makes to the contractile properties of HASMCs versus indirect effects 
through regulation of αSMA expression. However they indicate tensin1 is associated with αSMA transcription 
and, potentially, retention of the protein product within the cell.
Having investigated the expression and function of tensin1 in COPD, we next examined the association and 
functional effects of the COPD-associated SNP in the TNS1 gene, identified in GWAS14,13. The polymorphism is 
a non synonymous SNP (rs2571445) in the TNS1 gene and the base pair change encoded by this SNP leads to the 
amino acid substitution R1197W. The SNP is present in approximately 40% of the population, and its presence 
is associated with reduced lung function in GWAS14. It was therefore remarkable, that in spite of the relatively 
small number of subjects studied here, there was very strong segregation between homozygotes for C/C (which 
generates R1197) who were largely healthy, and patients with COPD or asthma who were predominantly hete-
rozygous C/T or occasionally homozygous T/T (R1197W). These data lend support to the GWAS findings. They 
suggest that R1197 in tensin1 is potentially protective against the development of both COPD and asthma, and/
or that R1197W is a factor promoting the development of COPD and asthma. The exact role that R1197W plays 
in COPD susceptibility remains unclear as we were unable to find any differences in gene expression or survival 
between cells expressing R1197W and those homozygous for R1197.
Figure 3. Tensin1 co-localises and correlates with αSMA in HASMCs. (A) Co-immunoprecipitation was 
carried out to investigate the interaction of tensin1 and αSMA. Tensin1 immunoprecipitates were analysed 
by western blotting analysis using an αSMA antibody. A band of 42 kDa was detected suggesting a physical 
interaction between tensin1 and αSMA. (B) Confocal immunofluorescent staining demonstrating co-
localisation of tensin1 (green) and αSMA (red) in HAMSCs. (C) Mander’s overlap coefficient and Pearson’s 
correlation were calculated to confirm association of the two proteins on n = 3 healthy and n = 3 COPD subjects 
(Mean ± SEM).
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Tensin1 protein expression was increased in the ASM bundles in COPD patients, but not in asthma, indi-
cating that its increased expression is associated with marked fixed airflow obstruction. These data suggest that 
tissue factors regulating tensin1 turnover may be important. The R1197W mutation is predicted to alter the pro-
tease sensitivity of the protein, and ex vivo samples supported differential tensin1 cleavage profiles in HASMCs 
derived from healthy and COPD tissue. We therefore hypothesize that the R1197W mutation and COPD-specific 
co-factors together modulate tensin1 degradation and thereby affect αSMA expression, and ASM mass (Fig. 6F, 
schema). This would rationalise the different observations in tissue from asthmatic patients.
In conclusion, we have demonstrated immunoreactivity for tensin1 in the ASM, lamina propria and airway 
epithelium in human lung tissue. Tensin1 expression was increased in the ASM and lamina propria in COPD 
donors when compared to non-disease controls, but was not increased in asthma. Tensin1 was enriched in fibril-
lar adhesions in HASMCs upon stimulation with TGFβ1 and fibronectin. This is likely of great importance as it 
allows tensin1 to interact with other proteins, leading to activation of signaling pathways and remodeling of the 
extracellular matrix. Furthermore tensin1 plays a critical role in regulating HASMC αSMA expression and con-
traction suggesting it may play an important role in both COPD and asthma pathophysiology.
Figure 4. Reduced αSMA mRNA and protein expression in tensin1-depleted HASMCs. Tensin1 siRNA-
transfected and control (untreated cells, transfection reagent alone, non-targeting siRNA control) HASMCs 
derived from healthy individuals and COPD patients were analysed for αSMA mRNA and protein expression. 
Cells were also stimulated with TGFβ1 to examine its role in αSMA expression after silencing tensin1. (A) 
The effects of depleting tensin1 on HASMC αSMA mRNA expression was examined using qRT-PCR on 
n = 4 COPD donors. αSMA mRNA expression was quantified using the 2−(ΔCt) method (Mean ± SEM). 
Silencing of tensin1 resulted in significant downregulation of αSMA mRNA in HASMCs when compared 
to control (p = 0.0011 by repeated measures ANOVA). *p < 0.05, **p < 0.01 by Sidaks multiple comparison 
test (Mean ± SEM). (B) Cells were transfected with siRNA directed against tensin1 and assessed for αSMA 
expression using immunofluorescence analysis. Tensin1-depleted HASMCs had a significantly lower intensity 
of αSMA when compared to controls both in the absence or presence of TGFβ1 (p = 0.0002 by repeated 
measures ANOVA). **p < 0.05, ** p < 0.01, *** p < 0.001 by Sidaks multiple comparison test. Mean ± SEM. 
Data in B are pooled COPD (n = 3) and healthy donors (n = 3) which did not differ. (C) The effects of depleting 
tensin1 on HASMC αSMA protein expression was also confirmed using western blot analysis (p = 0.0006 by 
repeated measures ANOVA). *p < 0.05, **p < 0.01 by Sidaks multiple comparison test. Mean ± SEM. The left 
panel shows a representative western blot. Data in the right panel are pooled COPD (n = 4) and healthy donors 
(n = 4) which did not differ.
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Methods
Subjects. COPD and control tissue for immunohistochemistry. To study COPD airway tissue by immuno-
histochemistry, we used 2nd-5th generation airway tissue collected at the time of lung resection for lung cancer. 
The tissue used was well demarcated from the tumour and not affected by the tumour process. The COPD group 
were all ex or current smokers with spirometric evidence of airflow obstruction and met Global Obstructive 
Lung Disease (GOLD) criteria for COPD26. Non-COPD control tissue was used from patients who did not have 
evidence of COPD (see Table 1).
Asthma and control tissue for immunohistochemistry. People with asthma and healthy controls underwent fibre-
optic bronchoscopy as described previously. Subjects with a history of asthma had a < 10 pack year smoking 
history and met a diagnosis for asthma as described previously20 (see Table 2).
Asthma and COPD tissue for primary human airway smooth muscle culture. For the study of primary human 
ASM cells (HASMCs) in culture, healthy control subjects and subjects with COPD or asthma underwent fibreop-
tic bronchoscopy as described previously20(see Table 3), and HASMCs cultured as described below.
All research participants gave written informed consent, and the collection of tissue was approved by the 
National Research Ethics Service (reference numbers: 07/MRE08/42, 04/Q2502/74, 08/H0406/189). All methods 
were performed in accordance with the relevant guidelines and regulations.
Figure 5. Collagen gel contraction by HASMC is dependent on tensin1. (A) Cells were transfected with 
siRNA directed against tensin1 and incubated within 3D collagen gels. The extent of spontaneous collagen gel 
contraction was recorded at 4, 18, 24 and 48 hours. Quantification of collagen gel contraction using gel area 
measurement was performed (n = 8, Mean ± SEM). Data shown are pooled COPD (n = 4) and healthy donors 
(n = 4) which did not differ. HASMCs transfected with tensin1 siRNA SMARTpool showed a greatly reduced 
ability to contract, with significant differences compared to controls at 18 (*p = 0.0118), 24 (**p = 0.0027) 
and 48 hours (****p = 0.0001) (Dunnett’s multiple comparison test as part of two-way ANOVA). (B) Cells 
were stimulated with bradykinin and collagen gel contraction was assessed on COPD (n = 4) and healthy 
donors (n = 4) (Mean ± SEM) after 18 hours. Contraction in tensin1 depleted HASMCs was greatly reduced 
(**p = 0.0033). The extent of collagen gel contraction following bradykinin stimulation was significantly 
increased in non- (***p = 0.0009), mock (***p = 0.0009) and siCON (***p = 0.0001) transfected cells, when 
compared to spontaneous contraction. Tensin1-depleted HASMCs did not respond significantly to bradykinin, 
when compared to controls (Tukey’s multiple comparison test as part of two-way ANOVA).
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Figure 6. The distribution of C and T alleles generating amino acid 1997 of tensin1 and schematic illustrating 
potential role of tensin1 in disease. (A) A diagram illustrating the base substitution at the site of the variant 
nucleotide base, the Eag1 restriction site formation in the presence of C versus T, and the different tensin1 
genotypes evident on digested PCR products. (B) pEGFP-C1 constructs with the tensin1 variants were used as 
controls to confirm validity of the RFLP technique. (C) An agarose gel image illustrating the different tensin1 
phenotypes in HAMSCs. Lane 1 = ladder. Lane 3 = Heterozygous, Lane 5, 7 and 9 = homozygous (-CC-) 
(encodes R1197 tensin1) and Lane 11 = homozygous (-TT-) (encodes R1197W tensin1). (D) Tensin1 mRNA 
expression was assessed between the different genotypes that segregated with health and disease. (E) A western 
blotting analysis illustrating differential cleavage of tensin1 in COPD subjects when compared to healthy 
controls (left). ‘PeptideCutter’ prediction tool showing differential cleavage at the site of mutation (right). (F) 
A schematic illustrating our hypothesis that the R1197W mutation and COPD-specific co-factors together 
modulate tensin1 degradation and thereby affect αSMA expression, and ASM mass.
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Human airway smooth muscle cell (HASMC) isolation and culture. Subjects underwent bron-
choscopy, and mucosal biopsies were collected for HASMC culture as described previously27. Pure human ASM 
bundles in bronchial biopsy tissue (n = 30) (and one lung resection sample) were dissected free of surrounding 
tissue. The ASM bundles were cultured in DMEM supplemented with 10% FCS, 4 mM L-glutamine, 100 U/ml 
penicillin, 100 mg/ml streptomycin, and 0.25 μg/ml amphotericin. HASMC characteristics were determined by 
immunofluorescence with antibodies to α-smooth muscle actin (αSMA) (FITC directly conjugated) and myosin 
indirectly labelled with FITC27.
Immunohistochemistry. Bronchial tissue remote from the cancer was dissected from the lung resection 
material and embedded in glycol‐methacrylate (GMA) and stored at −20 °C as described previously28. Bronchial 
biopsies taken at bronchoscopy were also embedded in GMA as described previously28. Two GMA sections of 2 
μm thickness and at least 10 µm apart were immunostained for Tensin1 (SAB4200283, 2.5 μg/ml, Sigma-Aldrich) 
or the appropriate isotype control at the same concentration as the primary antibody (X0936, 2.5 µg/ml, Dako) 
using the Dako EnVsion FLEX + staining technique. Sections were counter-stained using Mayer’s haematoxylin 
and visualised using a light microscope. The tensin1 antibodies were validated further using immunoprecipita-
tion and siRNA downregulation (see below).
Images of complete tissue sections were collected and tensin1 immunostaining was quantified by a blinded 
observer in the airway epithelium, lamina propria and airway smooth bundles using CellF software version 5.0 
(Olympus). The thresholding technique was used to quantify tensin1 immunostaining based on the hue satu-
ration and intensity (HSI) value as described previously20. Tensin1 immunostaining levels were correlated with 
smooth muscle bundle area measurements.
Quantitative real time PCR. HASMC RNAs were isolated using the RNeasy Plus Kit (Qiagen, Manchester, 
UK) according to manufacturer’s instructions. Detection of TNS1 and αSMA mRNA was performed using the 
Fast SYBR Green Master Mix, alongside primers targeting the internal normalised gene β-actin. PCR products 
were run on an agarose gel to confirm the product amplified was the correct size, and were also sequenced. TNS1 
and αSMA mRNA expression was quantified using the ΔCT method29. Full experimental details can be found in 
the Supplementary Information.
Cells were stimulated with 10 ng/ml transforming growth factor-β1 (TGFβ1) (R&D systems), cells were grown 
to confluence and then serum-starved for 24 hours prior to stimulation for a further 24 hours.
Western blotting. Tensin1 expression in primary HASMCs was analysed by western blotting as described 
previously30. HASMCs were disrupted in lysis buffer and soluble protein from equivalent number of cells was 
resolved by 7.5% SDS-page and then transferred to a polyvinylidene (PVDF) membrane. The membrane was 
blocked using 5% Milk +0.1% TBS Tween20 and incubated with antibodies to Tensin1 (SAB4200283, 1 μg/ml, 
Sigma-Aldrich), β-actin (sc-47778, 0.04 μg/ml Santa-Cruz) and αSMA (M0851, 1 µg/ml, Dako). Secondary anti-
bodies conjugated to horseradish peroxidase (HRP) were then applied (goat anti-rabbit HRP [sc-2054, 0.08 μg/
ml, Santa-Cruz] or goat anti-mouse HRP [P0447, 0.5 μg/ml, Dako]). Immunolabelled proteins were visualised 
by chemiluminescence using ECL substrate and the ImageQuant LA S 4000 (GE Healthcare Life Sciences, Little 
Chalfont, UK). Band intensity was quantified using ImageJ software (National Institutes of Health; http://rsbweb.
nih.gov/ij/).
Immunoprecipitation. HASMCs were disrupted in lysis buffer and as a pre-clearing step, incubated with 
Protein A/G beads (sc-2003, Santa-Cruz) for 30 minutes at 4 °C. Separately, Protein A/G beads were incubated 
with either anti-tensin1 antibody (SAB4200283, 4 µg/ml, Sigma-Aldrich or sc-28542, 2 µg/ml, Santa-Cruz) or 
isotype control rabbit IgG (X0936, 4 µg/ml, Dako) for 30 minutes at 4 °C. Pre-cleared lysates were then incubated 
with bead-antibody complexes for 16 hours at 4 °C. Immunoprecipitated complexes were washed three times 
in lysis buffer and once in PBS, eluted in Laemmli buffer, and denatured for 5 minutes at 95 °C. Western blot 
analysis was then performed. Immunoprecipitates were probed with two anti-tensin1 antibodies (Sigma-Aldrich 
[SAB4200283, 1 µg/ml] and Santa-Cruz [sc-28542, 4 µg/ml]) to examine tensin1 antibody specificity.
To examine tensin1-αSMA interaction, DynabeadsTM Protein G (10003D, ThermoFisher) were used. 
Again, HASMCs were disrupted in lysis buffer and as a pre-clearing step, incubated with Protein G Dynabeads 
for 1 hour at 4 °C. Pre-cleared lysates were then incubated with either anti-tensin1 antibody (SAB4200283, 
4 µg/ml, Sigma-Aldrich or sc-28542) or isotype control rabbit IgG (X0936, 4 µg/ml, Dako) for 4 hours 
Group Number
Genotype frequency, no. (%)
CC CT or TT
Healthy 14 11 (75%) 2 + 1 (25%)
COPD 12 — 11 + 1 (100%)
Asthma 9 1 (11.11%) 6 + 2 (88.89%)
Table 4. Genotype profile of healthy and diseased subjects for tensin1. HASMCs from 14 healthy controls, 
12 COPD subjects and 9 asthmatic subjects were genotyped for the two tensin1 variants. RFLP revealed 
the presence of the homozygous C/C (R1197) variant only in healthy controls, while COPD donors were 
predominantly T/C heterozygotes or occasionally T/T homozygotes (p < 0.0001). The distribution in asthma 
was similar to COPD (p = 0.0075).
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at 4 °C. Lysate-antibody complexes were then incubated with Protein G Dynabeads for 16 hours at 4 °C. 
Immunoprecipitated complexes were washed three times in lysis buffer and once in PBS, eluted in Laemmli buffer 
at room temperature for 30 minutes. Western blot analysis was then performed. Immunoprecipitates were probed 
with anti-αSMA (M0851, 1 µg/ml, Dako).
Immunofluorescence. HASMCs were seeded into 8-well chamber slides, grown to confluence, and immu-
nostained using mouse monoclonal αSMA (0.7 µg/ml, Dako) and isotype control FITC-conjugated mouse IgG2a 
(X0933, 10 µg/ml, Dako, Ely, UK), anti-Tensin1 antibody (4.5 µg/ml, Sigma-Aldrich) and isotype control rabbit 
IgG (4.5 µg/ml, Dako). Secondary antibodies labelled with AlexaFluor594 (A-11012, ThermoFisher) or FITC 
(FO382, Sigma-Aldrich) were applied and the cells were counterstained with 4′, 6-diamidino-2-phenylindole 
(DAPI) (32670, Sigma-Aldrich). To study the effect of the extracellular matrix protein fibronectin and TGFβ1 on 
tensin1 expression, slides were coated with human recombinant fibronectin (F0895, Sigma-Aldrich) for 1 hour 
prior seeding and stimulated with TGFβ1 (10 ng/ml) for 24 hours. When 50% confluent, cells were stained as 
above and mounted with fluorescent mounting medium. Original images were captured on a confocal immu-
nofluorescence microscope (Leica TCS SP5, UK) and staining was quantified using Cell F imaging software 
(Olympus UK Ltd). Matched exposures were used for isotype controls. Quantification of the co-localisation of 
tensin1 and αSMA proteins was performed using an Image J plugin, JaCoP, in which Mander’s overlap coefficient 
and Pearson’s correlation were calculated (National Institutes of Health; http://rsbweb.nih.gov/ij/). Quantification 
of fibrillar adhesion length was measured by Cell F imaging software (Olympus UK Ltd.).
Human airway smooth muscle cell transfection with siRNA. HASMCs were transfected with siRNA 
smartpools directed against TNS1 (M-009976-00, Dharmacon) and a non-targeting siRNA control (D-001206-
14, Dharmacon). HASMCs were plated in culture media in the absence of antibiotics in a 6 well plate and incu-
bated overnight. Lipofectamine 2000 (11668, Invitrogen) and siRNA mixture was added to cells. The cells were 
incubated with the complexes for 5 hours. After 5 hours, medium was replaced with antibiotic-free media for 
48 hours31. Tensin1 siRNA-transfected HASMCs derived from healthy and COPD individuals along with controls 
cells (untreated cells, transfection reagent alone, non-targeting siRNA control) were immunostained for both 
tensin1 (4.5 µg/ml, Sigma-Aldrich) and αSMA (0.7 µg/ml, Dako). Cells were also stimulated with TGFβ1 (10 ng/
ml) to examine its role on αSMA expression after silencing tensin1. Full experimental details can be found in the 
Supplementary information.
Survival/proliferation assay. The MTS assay (G3582, Promega) was used to assess survival and prolifer-
ation of the cells after tensin1 silencing. 48 hours after transfection, cells were collected and plated into 96-well 
plates in culture media in the absence of antibiotics overnight. Cells were stimulated with TGFβ1 for 24 hours. 
20 μl of MTS solution was added to each well. Plates were then incubated at 37 °C for 4 hours. The optical density 
(OD) at 490 nm was determined with a spectrophotometer. Each experimental condition was run in triplicate.
tGfβ1 ELISA. Tensin1 knockdown was performed as described above and supernatants were collected. A 
commercial ELISA was used to measure TGFβ1 in tensin1 knockdown sample supernatants according to the 
manufacturer’s protocol (DY240, R&D systems). Full experimental details can be found in the Supplementary 
Information.
Collagen gel contraction assay. Tensin1 knockdown was performed as above and then cells were 
detached and embedded in collagen gels as described previously32. Bradykinin was then added to appropri-
ate wells to a final concentration of 1 nM (B3259, Sigma-Aldrich). Photographs were taken at 0, 4, 18, 24 and 
48 hours. The surface area was measured at each time point using ImageJ software (National Institutes of Health; 
http://rsbweb.nih.gov/ij/).
SNP genotyping. PCR-restriction fragment length polymorphism (RFLP) analysis was used to genotype 
cultured cells for the presence of the polymorphism rs2571445. Full experimental details are provided in the 
Supplementary Information (can be found on the Supplementary information). The homozygote T/T genotype 
produced one band (278 bp), the homozygote C/C genotype produced two bands (214 and 64 bp) and the hete-
rozygote C/T genotype displayed all three bands (278, 214 and 64 bp).
Statistical analysis. Data distribution was tested for normality using the Kolmogorov-Smirnov test. Data 
across groups were compared with either the ANOVA or Kruskall Wallis tests where appropriate. Between group 
comparisons were analysed using Dunnett’s/Tukey’s multiple comparison test, or Students unpaired/paired t 
test, or Mann Whitney U/Wilcoxon Signed Rank for paired and unpaired parametric and non-parametric data, 
respectively. Data were analysed with GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA). P < 0.05 
was taken as statistically significant.
Ethical approval and consent to participate. All subjects gave written informed consent, and the col-
lection of tissue was approved by the National Research Ethics Service. Reference numbers: 07/MRE08/42, 04/
Q2502/74 and 08/H0406/189.
Data availability
All data generated or analysed during this study are included in this published article [and its Supplementary 
Information Files].
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